These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35240930)

  • 1. Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China.
    Hu Y; Pan X; Chen F; Wang Y; Liang H; Shen L; Chen Y; Lv H
    Hum Vaccin Immunother; 2022 Dec; 18(1):2035141. PubMed ID: 35240930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China.
    Pan X; Lv H; Liang H; Wang Y; Shen L; Chen F; Chen Y; Hu Y
    Hum Vaccin Immunother; 2022 Dec; 18(1):2021711. PubMed ID: 35108152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018-2020.
    Hu Y; Pan X; Shen L; Chen F; Wang Y; Liang H; Chen Y; Lv H
    Hum Vaccin Immunother; 2021 Dec; 17(12):5447-5453. PubMed ID: 34613883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the adverse events following immunization with inactivated quadrivalent influenza vaccine from 2018 to 2020 in Zhejiang province, with a comparison to trivalent influenza vaccine.
    Lv H; Pan X; Liang H; Wang Y; Hu Y
    Hum Vaccin Immunother; 2021 Nov; 17(11):4617-4622. PubMed ID: 34491888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia.
    Littlejohn ES; Clothier HJ; Perrett KP; Danchin M
    Hum Vaccin Immunother; 2015; 11(7):1828-35. PubMed ID: 26075435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world safety profile of the 9-valent human papillomavirus vaccine: A study in Zhejiang, China from 2019 to 2021.
    Chen F; Pan X; Liang H; Shen L; Wang Y; Chen Y; Lv H; Hu Y
    Hum Vaccin Immunother; 2022 Dec; 18(7):2152256. PubMed ID: 36484114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system.
    Pan X; Lv H; Chen F; Wang Y; Liang H; Shen L; Chen Y; Hu Y
    Hum Vaccin Immunother; 2021 Oct; 17(10):3823-3830. PubMed ID: 34170800
    [No Abstract]   [Full Text] [Related]  

  • 8. [The surveillance analysis of the adverse events following immunization of the domestic 13-valent pneumococcal polysaccharide conjugate vaccine in Zhejiang Province].
    Hu Y; Huang Z; Wang Y; Liang H; Pan XJ; Chen YP; Yuan L; Yang SY; Chen JJ; Chen YY; Yan XM; Tao Q; Qin X; Lyu HK
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Nov; 56(11):1625-1629. PubMed ID: 36372754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Adverse Events Post-13-Valent Pneumococcal Vaccination among Children in Hangzhou, China.
    Wang J; Du J; Liu Y; Che X; Xu Y; Han J
    Vaccines (Basel); 2024 May; 12(6):. PubMed ID: 38932305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance for adverse events following immunization from 2008 to 2011 in Zhejiang Province, China.
    Hu Y; Li Q; Lin L; Chen E; Chen Y; Qi X
    Clin Vaccine Immunol; 2013 Feb; 20(2):211-7. PubMed ID: 23239804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China.
    Lv H; Pan X; Liang H; Chen Y; Wang Y; Chen F; Shen L; Hu Y
    Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The characteristics and trend of adverse events following immunization reported by information system in Jiangsu province, China, 2015-2018.
    Hu R; Peng S; Liu Y; Tang F; Wang Z; Zhang L; Gao J; Guo H
    BMC Public Health; 2021 Jul; 21(1):1338. PubMed ID: 34229643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-marketing safety surveillance for both CRM197 and TT carrier proteins PCV13 in Jiangsu, China.
    Hu R; Liu Y; Zhang L; Kang G; Xu B; Li M; Yu J; Zhu Y; Guo H; Wang Z
    Front Public Health; 2023; 11():1272562. PubMed ID: 37908689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annual report: Surveillance of adverse events following immunisation in Australia, 2011.
    Mahajan D; Cook J; Dey A; Macartney K; Menzies RI
    Commun Dis Intell Q Rep; 2012 Dec; 36(4):E315-32. PubMed ID: 23330706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deaths reported to national surveillance for adverse events following immunization in China, 2010-2015.
    Wu W; Liu D; Nuorti JP; Li K; Xu D; Ye J; Zheng J; Cao L; Wang H
    Vaccine; 2019 Feb; 37(9):1182-1187. PubMed ID: 30709723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of reporting rates of adverse events following immunization: an international comparison of post-marketing surveillance programs with reference to China.
    Guo B; Page A; Wang H; Taylor R; McIntyre P
    Vaccine; 2013 Jan; 31(4):603-17. PubMed ID: 23200940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vaccine safety: description of the adverse events reported to the surveillance system in Chile, 2014 to 2016].
    Thomsen P O; Saldaña V A; Cerda L J; Abarca V K
    Rev Chilena Infectol; 2019 Aug; 36(4):461-468. PubMed ID: 31859770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers to healthcare workers reporting adverse events following immunization in Zhejiang province, China.
    Lv H; Pan X; Wang Y; Liang H; Yu H
    Hum Vaccin Immunother; 2022 Nov; 18(5):2083865. PubMed ID: 35820038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in adverse event reporting following immunization of hepatitis B vaccine among infants between 2013 to 2020 before and after the vaccine administration law in China.
    Wang C; Huang N; Lu QB; Black S; Liang X; Cui F
    Front Immunol; 2022; 13():956473. PubMed ID: 36248783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of death cases in Shenyang City, China, for immunization adverse event surveillance, 2009-2021.
    Gao D; Dong G; Zhu L; Jia N; Sun B
    Hum Vaccin Immunother; 2023 Aug; 19(2):2263225. PubMed ID: 37782096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.